Scalable Production of Therapeutic Protein Nanoparticles Using Flash Nanoprecipitation

2018 ◽  
Vol 8 (6) ◽  
pp. 1801010 ◽  
Author(s):  
Zhipeng Zeng ◽  
Cong Dong ◽  
Pengfei Zhao ◽  
Zhijia Liu ◽  
Lixin Liu ◽  
...  
2014 ◽  
Vol 2 (41) ◽  
pp. 17286-17290 ◽  
Author(s):  
Rui Liu ◽  
Chris Sosa ◽  
Yao-Wen Yeh ◽  
Fengli Qu ◽  
Nan Yao ◽  
...  

2015 ◽  
Vol 3 (6) ◽  
pp. 787-799 ◽  
Author(s):  
L. P. Herrera Estrada ◽  
J. A. Champion

This review describes nanoparticles made from protein by self-assembly or desolvation as carriers for the delivery of therapeutic proteins.


2021 ◽  
pp. 130523
Author(s):  
Rizwan Ahmed Bhutto ◽  
Zhinan Fu ◽  
Mingwei Wang ◽  
Jie Yu ◽  
Fang Zhao ◽  
...  

2020 ◽  
Author(s):  
Shogo Mori ◽  
Takahiro Aoki ◽  
Kaliyamoorthy Selvam ◽  
Shunichi Fukuzumi ◽  
Jieun Jung ◽  
...  

Despite the continuing popularity of radical reactions in organic synthesis, much remains to be explored in this area. Herein, we describe how spatiotemporal control can be exerted over the formation and reactivity of divergent exchangeable formamide radicals using nickel complexes with a semiconductor material (TiO<sub>2</sub>) under irradiation from near-UV–Vis light. Depending on the bipyridine ligand used and the quantity of the nickel complex that is hybridized on or nonhydridized over the TiO<sub>2</sub> surface, these radicals selectively undergo substitution reactions at the carbon center of carbon–bromine bonds that proceed via three different pathways. As the scalable production of formamides from CO<sub>2</sub> does not produce salt waste, these methods could add a new dimension to the search for carbon neutrality through the indirect incorporation of CO<sub>2</sub> into organic frameworks.


2020 ◽  
Vol 27 (35) ◽  
pp. 5856-5886 ◽  
Author(s):  
Chen Wang ◽  
Lukasz Kurgan

Therapeutic activity of a significant majority of drugs is determined by their interactions with proteins. Databases of drug-protein interactions (DPIs) primarily focus on the therapeutic protein targets while the knowledge of the off-targets is fragmented and partial. One way to bridge this knowledge gap is to employ computational methods to predict protein targets for a given drug molecule, or interacting drugs for given protein targets. We survey a comprehensive set of 35 methods that were published in high-impact venues and that predict DPIs based on similarity between drugs and similarity between protein targets. We analyze the internal databases of known PDIs that these methods utilize to compute similarities, and investigate how they are linked to the 12 publicly available source databases. We discuss contents, impact and relationships between these internal and source databases, and well as the timeline of their releases and publications. The 35 predictors exploit and often combine three types of similarities that consider drug structures, drug profiles, and target sequences. We review the predictive architectures of these methods, their impact, and we explain how their internal DPIs databases are linked to the source databases. We also include a detailed timeline of the development of these predictors and discuss the underlying limitations of the current resources and predictive tools. Finally, we provide several recommendations concerning the future development of the related databases and methods.


Author(s):  
Shazid Md. Sharker ◽  
Md. Atiqur Rahman

Most of clinical approved protein-based drugs or under in clinical trial have a profound impact in the treatment of critical diseases. The mammalian eukaryotic cells culture approaches, particularly the CHO (Chinese Hamster Ovary) cells are mainly used in the biopharmaceutical industry for the mass-production of therapeutic protein. Recent advances in CHO cell bioprocessing to yield recombinant proteins and monoclonal antibodies have enabled the expression of quality protein. The developments of cell lines are possible to upgrade specific productivity. As a result, it holds an interesting area for academic as well as industrial researchers around the world. This review will concentrate on the recent progress of the mammalian CHO cells culture technology and the future scope of further development for the mass-production of protein therapeutics.


2019 ◽  
Vol 5 (2) ◽  
pp. 58-66
Author(s):  
Luísa Carvalho

The presence of subvisible particles (SVPs) in parenteral formulations of biologics is a major challenge in the development of therapeutic protein formulations. Distinction between proteinaceous and non-proteinaceous SVPs is vital in monitoring formulation stability.


Sign in / Sign up

Export Citation Format

Share Document